Following a diagnosis of breast cancer, the most immediate challenges in patient
management are the determination of prognosis and identification of the most appropriate …

Breast cancer (BC) affects over 250,000 women in the US each year. Drug-resistant cancer
cells are responsible for most breast cancer fatalities. Scientists are developing novel …

Background Neoadjuvant treatment with a dual anti-human epidermal growth factor receptor
2 (HER2) blockade with pyrotinib and trastuzumab has been shown to be effective for HER2 …

Obesity is associated with an increased risk of breast cancer (BC) and poorer outcome. We
assessed the impact of body mass index (BMI) on pathological complete response (pCR) …

Considerable variety in how patients respond to treatments, driven by differences in their
geno-and/or phenotypes, calls for a more tailored approach. This is already happening, and …

Breast cancer is a heterogeneous disease comprised of four molecular subtypes defined by
whether the tumor-originating cells are luminal or basal epithelial cells. Breast cancers …

Biological agents or “biologics” are widely used in oncology practice for cancer treatment
and for the supportive management of treatment-related side effects. Unlike small-molecule …

Drug-induced liver injury (DILI) due to chemotherapeutic drugs is a significant cause of
morbidity and mortality. Most cases of chemotherapy-induced hepatotoxicity are …

Abstract The phosphoinositide 3-kinase (PI3K) signaling pathway is well-known for its
important role in cancer growth, proliferation and migration. The activation of PI3K pathway …

Targeting tumors using miniature antibodies is a novel and attractive therapeutic approach,
as these biomolecules exhibit low immunogenicity, rapid clearance, and high targeting …